Fig. 6: Applicability of AA15V LNP-sSE-SCTs in multiple tumor models and human tumor samples.

a Schematic of the treatment regimen in B16F10 tumor model treated with the combination of AA15V LNP-sSE-SCTs and ICI. b Tumor volumes over time. c Survival rates of mice bearing B16F10 tumor. d Schematic of the treatment regimen in A20 tumor model. e Tumor volumes over time. f Survival rates of the mice bearing A20 tumor. g Schematic depicting ex vivo AA15V LNP-sSE-SCTs delivery in human tumor tissues. Created in BioRender. Xue, Y. (2025) https://BioRender.com/q02v567. h Expression of H-2Kb⁺β2m⁺ expression in CD45⁻ cells from pediatric glioma dissections after ex vivo treatment with AA15V LNP-sSE-SCTs. i, j H-2Kb⁺β2m⁺ in CD45⁻ cells from two separate lung left lower lobe (LLL) adenocarcinoma specimens after ex vivo treatment with AA15V LNP-sSE-SCTs. Data in (b, c) are from n = 6 (PBS group) and 8 (SCT groups) biologically independent samples, respectively. Data in (e, f) are from n = 6 (PBS group and UnVac groups) and 7 (Vac groups) biologically independent samples, respectively. Data in (h) and (j) are from n = 3 individual tissue slices. Data in (i) are from n = 4 individual tissue slices. Data are presented as mean ± SD. Statistical significance in (b, e) and (h–j) was determined by the two-tailed Student’s t-test. Statistical significance in (c) and (f) was determined by the log-rank (Mantel–Cox) test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.